Following people at risk of fatty liver disease to detect liver scarring
Follows people with obesity, type 2 diabetes or heavy alcohol use over many years.
Plain-language title generated from the registry record
Registry title: Detecting Liver Fibrosis in Patients At-risk
Key facts
- Where
- Stavanger, NorwaySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 40 to 70 who are at risk of fatty liver disease because of overweight or obesity, type 2 diabetes, or risky or harmful alcohol use.
- Age
- 40 to 70 years
- Sex
- Women and men can both join.
Main reasons for not taking part
- People who cannot give informed consent
- People outside the age range of 40 to 70 years
- People with other conditions that, in the investigator's assessment, rule out taking part
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 70 years old?
Source: NCT07775638, who can take part
Where in Norway
- Stavanger University HospitalStavanger, NorwayContact: Forskningsposten, Stavanger University HospitalNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Helse Stavanger HF
- Trial code
- NCT07775638
- Record updated
- 20 August 2026
- Original description
The project will establish a research cohort (called STELIR; STEatotisk Liver-risk In Rogaland) based on a biobank with an associated health register. The purpose is to collect, store and analyze biological material and clinical data from people at risk of steatotic liver disease (fatty liver disease). The research cohort will consist of individuals who agree to participate and will be followed over many years with planned examinations/tests at baseline, after 2 years, after 5 years and every 5 years thereafter. The STELIR cohort consists of individuals between 40 and 70 years of age who have one or more of the following risk factors: Obesity, type 2 diabetes or hazardous or harmful alcohol consumption.Read full original descriptionShow less
Detecting Liver Fibrosis in Patients At-risk
The project will establish a research cohort (called STELIR; STEatotisk Liver-risk In Rogaland) based on a biobank with an associated health register. The purpose is to collect, store and analyze biological material and clinical data from people at risk of steatotic liver disease (fatty liver disease). The research cohort will consist of individuals who agree to participate and will be followed over many years with planned examinations/tests at baseline, after 2 years, after 5 years and every 5 years thereafter. The STELIR cohort consists of individuals between 40 and 70 years of age who have one or more of the following risk factors: Obesity, type 2 diabetes or hazardous or harmful alcohol consumption.
The biological material and clinical data collected will be stored and used for research on liver-related disease risk, diagnostics and treatment.
Inclusion: Age 40 to 70 years at the time of inclusion; At least one of the following risk factors: Overweight or obesity, type 2 diabetes mellitus, risky or harmful alcohol consumption; Ability to provide written informed consent.
Exclusion: Other conditions precluding participation based on investigator assessment; Individuals outside the defined age range; Inability to give informed consent.